Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Rev. chil. infectol ; 38(1): 15-21, feb. 2021. tab
Article in Spanish | LILACS | ID: biblio-1388199

ABSTRACT

INTRODUCCIÓN: Taurolidina es una molécula con propiedades anti-endotóxicas, antimicrobianas y anti-inflamatorias, que inhibe la adhesión bacteriana, lo que ha permitido usarla como terapia de sellado en catéter venoso central de larga duración (CVC) para prevenir infecciones del torrente sanguíneo asociadas a CVC (ITS-CVC). OBJETIVO: Dar a conocer una experiencia preliminar, la primera en Chile, con taurolidina como terapia de sellado para prevenir ITS-CVC y reportar su eficacia. MÉTODO: Se instiló una solución en base a taurolidina en el CVC de tres niños con insuficiencia intestinal, dependientes de alimentación parenteral, atendidos en un hospital terciario de la Región de Valparaíso, y se comparó la tasa de ITS-CVC antes y después de su uso mediante un análisis retrospectivo. RESULTADOS: en los dos pacientes que iniciaron terapia de sellado inmediatamente después de instalado el CVC, la tasa de ITS-CVC se logró llevar a cero, mientras que, en el tercero, portador de un CVC instalado 9 meses antes, con ITS-CVC recurrentes, un nuevo episodio de ITS-CVC obligó a suspender la profilaxis. CONCLUSIONES: La terapia de sellado con solución en base a taurolidina previno las ITS-CVC cuando ésta se inició al momento de instalarse el CVC, no así en un CVC antiguo con ITS-CVC recurrentes.


BACKGROUND: Taurolidine is a molecule with anti-endotoxic, anti-microbial and anti-inflammatory properties that inhibits bacterial adhesion, allowing for its use as lock therapy for the prevention of catheter-related bloodstream infections (CRBSI) in long-term central venous catheters (CVC). AIM: To report a preliminary experience, the first one in Chile, using lock therapy with taurolidine for the prevention of CRBSI and to report its efficacy. METHOD: A taurolidine-based solution was instilled in the CVC of three children with intestinal insufficiency dependent on parenteral nutrition, attended in a Chilean tertiary hospital, and the rate of CRBSI before and after its use was compared in retrospect. RESULTS: In the two patients who started lock therapy immediately after the installation of their CVC, the rate of CRBSI was brought to zero, whereas in the third patient, who had a 9 months-old CVC with a recurrent CRBSI history, an intercurrent CRBSI forced discontinuation of the prophylaxis. CONCLUSIONS: Lock therapy with a taurolidine-based solution prevented CRBSIs when it was begun immediately after installing the CVC, in contrast with an old CVC with a history of recurrent CRBSIs.


Subject(s)
Humans , Infant , Child , Thiadiazines , Catheterization, Central Venous , Bacteremia , Catheter-Related Infections , Taurine/analogs & derivatives , Thiadiazines/therapeutic use , Catheterization, Central Venous/adverse effects , Chile , Catheter-Related Infections/prevention & control , Tertiary Care Centers
2.
Rev. chil. infectol ; 36(4): 414-420, ago. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1042656

ABSTRACT

Resumen Taurolidina es un antiséptico de amplio espectro usado como solución de terapia de sellado (lock therapy) en adultos y niños portadores de catéter venoso central de larga duración (CVC) para prevenir las infecciones asociadas a CVC (IACVC). No induce desarrollo de resistencia y tiene efectos adversos leves y fugaces, lo que lo convierte en una alternativa, tanto como terapia de sellado como para la profilaxis de las IACVC, en este grupo de pacientes.


Taurolidine is a broad-spectrum antiseptic used as lock therapy solution in adult and pediatric patients with long term central venous catheters (CVC) for the prevention of catheter related bloodstream infections (CRBSI). Taurolidine doesn't induce the resistant development and has only minor and brief side effects, which makes it an alternative both as a lock therapy and for the prevention of CRBSI in this group of patients.


Subject(s)
Humans , Taurine/analogs & derivatives , Thiadiazines/administration & dosage , Catheter-Related Infections/prevention & control , Central Venous Catheters/adverse effects , Anti-Infective Agents, Local/administration & dosage , Taurine/administration & dosage
3.
Bol. micol. (Valparaiso En linea) ; 32(1): 19-22, jun. 2017. ilus
Article in Spanish | LILACS | ID: biblio-868820

ABSTRACT

Las levaduras del género Rhodotorula son patógenos oportunistas emergentes, especialmente en pacientes inmunocomprometidos. Se presenta el caso de un niño de 9 años con sarcoma de Ewing en tratamiento con quimioterapia que cursó con una probable fungemia por Rhodotorula mucilaginosa. Se identificaron varios factores de riesgo tales como la presencia de un catéter venoso central (CVC) y una neoplasia maligna sólida. El diagnóstico se realizó a través de un hemocultivo de una rama del CVC. Nuestra cepa fue identificada como R. Mucilaginosa por morfofisiología y pruebas bioquimicas. El éxito terapeutico se basó en el retiro del CVC y en el tratamiento con anfotericina B desoxicolato como primera alternativa.


Yeasts from Rhodotorula genus are opportunistic pathogen that emerge especially in immunocompromised patients. We report a case of a 9-years-old boy, he developed an Ewing’s sarcoma that was treated with chemotherapy an underwent with problable fungemia by Rhodotorula mucilaginosa. Several risk factors were identified such as presence of a central venous catheter (CVC) and a solid malignant neoplasm. The diagnosis was made by blood culture of a branch of the CVC. Our isolated was identified as R. mucilaginosa by morphofisiology and biochemical test. The therapy did success based on withdrawal of CVC and treatment with amphotericin B deoxycholate as the first alternative.


Subject(s)
Humans , Male , Child , Central Venous Catheters/adverse effects , Central Venous Catheters/microbiology , Catheter-Related Infections/diagnosis , Catheter-Related Infections/drug therapy , Rhodotorula/pathogenicity , Rhodotorula/chemistry , Immunocompromised Host , Risk Factors , Sarcoma, Ewing
SELECTION OF CITATIONS
SEARCH DETAIL